NAFLD: Accurate quantification of hepatic fat-is it important?

Nature Reviews Gastroenterology and Hepatology

Volumn 12, Issue 3, 2015, Pages 126-127

  Adams, Leon A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; PLACEBO; TRIACYLGLYCEROL;

CELL DEATH; DISEASE SEVERITY; ECHOGRAPHY; FATTY LIVER; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING DERIVED PROTON DENSITY FAT FRACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; ANIMAL; FEMALE; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ANIMALS; FATTY LIVER; FEMALE; HUMANS; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84924254686     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2015.23     Document Type: Short Survey

References (10)

1. Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221-1231 (2002).
2. Lin, S. C. et al. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique. Clin. Gastroenterol. Hepatol. http://dx.doi.org/10.1016/j.cgh.2014.11.027.
3. Loomba, R. et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel MRI and MRE in a randomized trial (MOZART Trial). Hepatology http://dx.doi.org/10.1002/hep.27647.
4. Targher, G., Day, C. P. & Bonora, E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363, 1341-1350 (2010).
5. Noureddin, M. et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 58, 1930-1940 (2013).
6. Korenblat, K. M., Fabbrini, E., Mohammed, B. S. & Klein, S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 134, 1369-1375 (2008).
7. Lambert, J. E., Ramos-Roman, M. A., Browning, J. D. & Parks, E. J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146, 726-735 (2014).
8. Sanyal, A. J. et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54, 344-353 (2011).
9. Neuschwander-Tetri, B. A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52, 774-788 (2010).
10. Loomba, R. et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 60, 1920-1928 (2014).